Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY:EW)

76.66 +0.44 (+0.58%)
Official Closing Price Updated: 4:10 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Boston Scientific Discontinues Worldwide Sales Of Acurate Aortic Valve Systems: But Retail Sentiment Brightens
The company said in a regulatory filing that the decision was made in light of increased clinical and regulatory requirements to maintain regulatory approvals in global markets and to obtain approvals... 
Via Stocktwits
Exposures Product Safety
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott
The company said the regulatory path forward for one of its key systems is too murky to pursue. 
Via Investor's Business Daily
Exposures Product Safety
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts
Via Benzinga
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
From Edwards Lifesciences Corporation
Via Business Wire
What's going on in today's pre-market session: S&P500 movers
Get insights into the top gainers and losers in the S&P500 index of Tuesday's pre-market session. 
Via Chartmill
P/E Ratio Insights for Edwards Lifesciences
Via Benzinga
Earnings Scheduled For April 23, 2025
Via Benzinga
Edwards Lifesciences Corp (NYSE:EW) - A Technical Breakout Candidate Worth Watching
Edwards Lifesciences (NYSE:EW) shows strong technicals and a consolidation pattern, making it a breakout candidate. Resistance at $76.76 could signal further upside if broken. 
Via Chartmill
What's Driving the Market Sentiment Around Edwards Lifesciences?
Via Benzinga
Edwards Lifesciences to Present at the BofA Securities 2025 Health Care Conference
From Edwards Lifesciences Corporation
Via Business Wire
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
From Edwards Lifesciences Corporation
Via Business Wire
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
In today's session, there are S&P500 stocks with remarkable trading volume.
Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below. 
Via Chartmill
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook Brightens
Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong global demand. 
Via Benzinga
What's going on in today's session: S&P500 movers
Get insights into the S&P500 index performance on Thursday. Explore the top gainers and losers within the S&P500 index in today's session. 
Via Chartmill
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Thursday's pre-market session: top gainers and losers in the S&P500 index
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat
Edwards Lifesciences stock was flat late Wednesday after the medtech company beat profit views and delivered in-line sales. 
Via Investor's Business Daily
Topics ETFs
Edwards Lifesciences Reports First Quarter Results
From Edwards Lifesciences Corporation
Via Business Wire
Stocks Surge On China Tariff Hopes, Tesla Jumps, Gold Loses Shine: What's Driving Markets Wednesday?
Risk-on sentiment dominated Wall Street on Wednesday, as upbeat earnings reports and conciliatory messages from the Trump administration helped lift investor confidence. 
Via Benzinga
Topics Government
Exposures Political
A Look at Edwards Lifesciences's Upcoming Earnings Report
Via Benzinga
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue
From Edwards Lifesciences Corporation
Via Business Wire
Is Edwards Lifesciences Gaining or Losing Market Support?
Via Benzinga
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025
From Edwards Lifesciences Corporation
Via Business Wire
Edwards SAPIEN M3 Receives CE Mark, Becoming World’s First Transfemoral Transcatheter Mitral Valve Replacement System
From Edwards Lifesciences Corporation
Via Business Wire
Edwards Lifesciences Stock: A Deep Dive Into Analyst Perspectives (9 Ratings)
Via Benzinga
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
New Data Confirm Rapid, Unpredictable Progression of Severe Aortic Stenosis and Need for Urgent Referral and Evaluation of Patients
From Edwards Lifesciences Corporation
Via Business Wire
Jim Cramer: Healthpeak Properties Is A 'Reasonable' REIT, Recommends Buying This Health Care Stock
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.